Indraprastha Medical Corporation Ltd.
-
NSE: INDRAMEDCO
-
BSE: 532150
-
Q
-
V
-
T
Quality Score
High Financial StrengthValuation Score
Affordable ValuationTechnical Score
Technically Moderately BullishBroker average target upside %
587.60 %
Market Leader
TTM PE Ratio
9.70
Below industry Median
Price to Book Ratio
2.20
Below industry Median
Operating Revenues Qtr Cr
274.00 Cr
Above industry Median
Net Profit Qtr Cr
19.80 Cr
Above industry Median
RSI
70.60
RSI Overbought
MFI
75.60
MFI Overbought
MACD
1.60
MACD above Signal and Center
MACD Signal Line
1.00
MACD above Signal and Center
30Day SMA Rs
85.30 Rs
Price above SMA 85.26
50Day SMA Rs
83.30 Rs
Price above SMA 83.34
100Day SMA Rs
83.30 Rs
Price above SMA 83.33
200Day SMA Rs
78.70 Rs
Price above SMA 78.73
Promoter holding %
51.00
No change in Promoter holding
FII holding current Qtr %
0.27
FII holdings fell by 0.50%
MF holding current Qtr %
0.00
MF holding at 0.00%
Institutions holding %
0.27
Institutions holding decreased by 0.5000%.
Broker Average Rating
5.00
Broker Average Rating
Broker Covering stock
1.00
1 Broker Covering stock
Broker 1Year total
1.00
1 Broker 1Year total
Broker 6M Reco downgrade
0.00
0 Broker 6M Reco downgrade
Broker 6M Reco upgrade
0.00
0 Broker 6M Reco upgrade
Broker 6M Target downgrade
0.00
0 Broker 6M Target downgrade
Broker 6M Target upgrade
0.00
0 Broker 6M Target upgrade
Momentum score
64.42
Technically Moderately Bullish
Valuation score
62.67
Affordable Valuation
Quality score
87.53
High Financial Strength
-
- 2023-05-24T08:00:18+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit copies of the public notice of the financial results, published on 24th May, 2023, in the 'Financial Express', all India editions, in English language and in 'Jansatta', Delhi edition, in Hindi language.
Read More -
- 2023-05-23T11:57:10+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Related Party Transactions For The Half Year Ended 31St March, 2023
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions for the half year ended 31st March, 2023.
Read More -
- 2023-05-23T11:48:17+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Results For The Financial Year Ended 31St March, 2023 And Recommendation Of Dividend
This is to inform that the Board of Directors of the Company has, at its meeting held on Tuesday, 23rd May, 2023 (i.e. today), inter-alia : 1. Approved the Audited Financial Statements for the year ended 31st March, 2023 and Audited Financial Results for the quarter/year ended 31st March, 2023, as recommended by the Audit Committee; and 2. Recommended a dividend @ 30% i.e. Rs. 3.00 per share for the financial year 2022-23. The meeting of the Board of Directors commenced at 3.00 p.m. and concluded at 5:00 p.m. We shall inform you in due course of time, the date on which the Company will hold its Annual General Meeting for the year ended 31st March, 2023, and the date from which dividend, if approved by the shareholders, will be paid or warrants thereof dispatched to the shareholders.
Read More -
- 2023-05-23T11:43:05+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 23Rd May, 2023
This is to inform that the Board of Directors of the Company has, at its meeting held on Tuesday, 23rd May, 2023 (i.e. today), inter-alia : 1. Approved the Audited Financial Statements for the year ended 31st March, 2023 and Audited Financial Results for the quarter/year ended 31st March, 2023, as recommended by the Audit Committee; and 2. Recommended a dividend @ 30% i.e. Rs. 3.00 per share for the financial year 2022-23. Pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, The meeting of the Board of Directors commenced at 3.00 p.m. and concluded at 5:00 p.m. We shall inform you in due course of time, the date on which the Company will hold its Annual General Meeting for the year ended 31st March, 2023, and the date from which dividend, if approved by the shareholders, will be paid or warrants thereof dispatched to the shareholders.
Read More -
- 2023-05-16T07:52:55+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit Annual Secretarial Compliance Report from a practicing Company Secretary, for the year ended 31st March, 2023. This is for your information and record.
Read More -
- 2023-05-12T11:42:26+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit copies of the public notice of the date of the Board meeting, published on 12th May, 2023, in the 'Financial Express', all India editions, in English language and in 'Jansatta', Delhi edition, in Hindi language. You are requested to take the above information on record.
Read More -
- 2023-05-11T07:51:59+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Board Meeting Intimation for Board Meeting To Consider And Approve Audited Financial Results And Dividend, If Any, For The Financial Year 2022-23
INDRAPRASTHA MEDICAL CORP.LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that a meeting of the Board of Directors of the Company will be held on Tuesday, 23rd May, 2023, inter alia: - a) to consider and approve the audited financial results for the quarter/ year ended 31st March, 2023; and b) to consider and recommend dividend, if any, on equity shares of the Company for the financial year 2022-23.
Read More -
- 2023-04-26T11:46:00+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyINDRAPRASTHA MEDICAL CORP.LTD. 2CIN NO.L24232DL1988PLC030958 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRIYA RANJAN Designation: AVP CORPORATE AFFAIRS LEGAL EmailId: priya_r@apollohospitalsdelhi.com Name of the Chief Financial Officer: C P TYAGI Designation: CHIEF FINANCIAL OFFICER EmailId: tyagi@apollohospitalsdelhi.com Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Read More -
- 2023-04-15T08:03:51+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that ICRA Limited has given long term credit ratings at [ICRA]AA (pronounced ICRA Double A) for Rs. 62.50 crore bank facilities and short term credit ratings at [ICRA]A1+ (pronounced ICRA A One Plus) for Rs. 40.0 crore Commercial Paper to the Company.
Read More -
- 2023-04-15T08:01:39+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliance Certificate Under Regulation 40(10)
Pursuant to Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find a copy of the certificate from a practicing Company Secretary certifying that all certificates have been issued, for the financial year ended 31st March, 2023, within 30 days of the date of lodgment for
Read More -
- 2023-04-13T10:41:35+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliance Certificate For The Period Ended 31St March, 2023
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find the compliance certificate for the period 1st April, 2022 to 31st March, 2023.
Read More -
- 2023-04-13T10:38:23+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, enclosed please find herewith a Certificate dated 5th April, 2023, issued by M/s. Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company, for the quarter ended 31st March, 2023.
Read More -
- 2023-03-23T09:24:30+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Closure of Trading Window
Pursuant to the provisions of the Code of Conduct for Prevention of Insider Trading, under SEBI (Prohibition of Insider Trading) Regulations, 2015, it is hereby informed that Trading Window for dealing in shares of the Company, will remain closed with effect from 1st April, 2023 till 48 hours after the declaration of audited financial results for the quarter / year ending 31st March, 2023. The date of the Board Meeting to consider the audited financial results for the quarter / financial year ending 31st March, 2023, shall be intimated separately.
Read More -
- 2023-03-21T06:13:07+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform you that the Company has issued duplicate share certificate in respect of Share Certificates reported to be lost by the shareholders. In accordance with Regulation 39(3) of the Regulations, the details of the said share certificates are as given below: Name of the Shareholder Folio no. No. of shares Old Certificate Nos. Distinctive Nos. New Certificate No. Rajni Chawla Jt. Satpal Chawla 21868 100 179486 77114501-77114600 209865 Manoj Kr. Jain 12014 600 93767 - 93772 77530201-77530800 209864 This is for your information and record.
Read More -
- 2023-02-13T11:44:36+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform you that the Company has received intimation from the shareholders on 11th February, 2023, regarding loss of share certificates. In accordance with Regulation 39(3) of the Regulations, the details of the said share certificates are as given below: Name of the Shareholder Folio no. No. of shares Certificate Nos. Distinctive Nos. Rajni Chawla Jt. Satpal Chawla 21868 100 179486 77114501-77114600 Manoj Kr. Jain 12014 600 93767 - 93772 77530201-77530800 This is for your information and record.
Read More -
- 2023-02-08T12:14:56+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December, 2022
This is to inform that the Board of Directors of the Company has, at its meeting held on Wednesday, 8th February, 2023 (i.e. today), inter-alia, considered and approved the Un-audited Financial Results for the quarter and nine months ended 31st December, 2022, along with the Limited Review Report of the statutory auditor. We are enclosing herewith the Un-audited Financial Results for the quarter and nine months ended 31st December, 2022, along with a copy of the Limited Review Report by the Statutory Auditors of the Company. The Board meeting commenced at 3.00 p.m. and ended at 5.30 p.m.
Read More -
- 2023-02-08T12:10:39+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 8Th February, 2023
This is to inform that the Board of Directors of the Company has, at its meeting held on Wednesday, 8th February, 2023 (i.e. today), inter-alia, considered and approved the Un-audited Financial Results for the quarter and nine months ended 31st December, 2022, along with the Limited Review Report of the statutory auditor. We are enclosing herewith the Un-audited Financial Results for the quarter and nine months ended 31st December, 2022, along with a copy of the Limited Review Report by the Statutory Auditors of the Company. The Board meeting commenced at 3.00 p.m. and ended at 5.30 p.m.
Read More -
- 2023-01-23T07:36:13+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Board Meeting Intimation for Consider And Approve Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2022
INDRAPRASTHA MEDICAL CORP.LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that a meeting of the Board of Directors of the Company will be held on Wednesday, 8th February, 2023, to consider and approve, the unaudited financial results for the quarter and nine months ended 31st December, 2022.
Read More -
- 2023-01-14T05:29:00+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, enclosed please find herewith a Certificate dated 5th January, 2023, issued by M/s. Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company, for the quarter ended 31st December, 2022. This is for your information and record.
Read More -
- 2022-12-24T07:27:46+00:00
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Closure of Trading Window
Pursuant to the provisions of the Code of Conduct for Prevention of Insider Trading, under SEBI (Prohibition of Insider Trading) Regulations, 2015, it is hereby informed that Trading Window for dealing in shares of the Company, will remain closed with effect from 1st January, 2023 till 48 hours after the declaration of un-audited financial results for the quarter and nine months ending 31st December, 2022. The date of the Board Meeting to consider the un-audited financial results for the quarter and nine months ending 31st December, 2022, shall be intimated separately.
Read More
| Ex-date | Dividend Amount | Dividend Type | Record Date |
|---|
Bonus History
Adani Ports & Special Economic Zone Ltd. has not announced any bonus since Jan 1, 2000.
Check out stocks with top dividendAdani Ports & Special Economic Zone Ltd. has split the face value 1 time since Sept. 23, 2010. Adani Ports & Special Economic Zone Ltd. had last split the face value of its shares from Rs 10 to Rs 2 in 2016.The share has been quoting on an ex-split basis from Sept. 23, 2010.
| Ex-date | Old FV | New FV | Record Date |
|---|---|---|---|
| Sept. 23, 2010 | 10 | FINAL | Sept. 24, 2010 |